靶向融合活检结局在泌尿外科医生层面的院内差异
研究纳入2017年8月至2019年3月在密歇根医学中心接受融合活检的1133例患者,由5名医生操作。调整患者年龄、PSA、种族、家族史、前列腺体积、临床分期和PI-RADS评分后,靶向临床显著癌检出率在医生间无显著差异(范围38.5%-46.9%,校正P值=.575)。按PI-RADS分层,PI-RADS 4病灶的临床显著癌检出率在医生间差异有统计学意义(范围24.6%-43.4%,校正P=.003)。
要点
- 调整混杂因素后,靶向临床显著癌总检出率在5名医生间无显著差异(38.5%-46.9%,校正P=.575)。
- PI-RADS 4病灶的临床显著癌检出率在医生间差异有统计学意义(24.6%-43.4%,校正P=.003)。
- PI-RADS 3和PI-RADS 5病灶的检出率在医生间无显著差异(未校正P=.838;校正P=.766)。
核心结论
- PI-RADS 4病灶的临床显著前列腺癌检出率在泌尿外科医生间存在统计学显著差异。
- 作者认为,即使在有经验的医生中,医生层面的差异也可能导致PI-RADS 4病灶临床显著癌检出率的不同。
- 活检技术、影像科医生判读和MR采集方案的相对影响需进一步研究。
研究设计与样本
- 回顾性队列研究,纳入密歇根泌尿外科手术改进协作组(MUSIC)临床注册库中2017年8月至2019年3月在密歇根医学中心接受融合活检的全部男性。
- 共纳入1133例融合活检,由5名医生操作。
- 主要结局为靶向穿刺针中临床显著癌(定义为Gleason分级≥2)检出率,以及按PI-RADS评分分层的靶向穿刺针临床显著癌检出率。
- 采用双变量和多变量逻辑回归分析。
主要发现
- 调整患者年龄、PSA、种族、家族史、前列腺体积、临床分期和PI-RADS评分后,靶向临床显著癌检出率在医生间无显著差异(范围38.5%-46.9%,校正P值=.575)。
- PI-RADS 3病灶的临床显著癌检出率范围为11.1%-16.7%(未校正P=.838)。
- PI-RADS 4病灶的临床显著癌检出率范围为24.6%-43.4%(校正P=.003)。
- PI-RADS 5病灶的临床显著癌检出率范围为69.4%-78.8%(校正P=.766)。
局限性
- 活检技术、影像科医生判读和MR采集方案的相对影响需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the extent to which the urologist performing biopsy contributes to variation in prostate cancer detection during fusion-guided prostate biopsy. METHODS: All men in the Michigan Urological Surgery Improvement Collaborative (MUSIC) clinical registry who underwent fusion biopsy at Michigan Medicine from August 2017 to March 2019 were included. The primary outcomes were clinically significant cancer detection rate (defined as Gleason Grade ≥2) in targeted cores and clinically significant cancer detection on targeted cores stratified by PI-RADS score. Bivariate and multivariable logistic regression analyses were performed. RESULTS: A total of 1133 fusion biopsies performed by 5 providers were included. When adjusting for patient age, PSA, race, family history, prostate volume, clinical stage, and PI-RADS score, there was no significant difference in targeted clinically significant cancer detection rates across providers (range = 38.5%-46.9%, adjusted P-value = .575). Clinically significant cancer detection rates ranged from 11.1% to 16.7% in PI-RADS 3 (unadjusted P = .838), from 24.6% to 43.4% in PI-RADS 4 (adjusted P = .003), and from 69.4% to 78.8% in PI-RADS 5 (adjusted P = .766) lesions. CONCLUSION: There was a statistically significant difference in clinically significant prostate cancer detection in PI-RADS 4 lesions across providers. These findings suggest that even among experienced providers, variation at the urologist level may contribute to differences in clinically significant cancer detection rates within PI-RADS 4 lesions. However, the relative impact of biopsy technique, radiologist interpretation, and MR acquisition protocol requires further study.
引用
- Dhir A, Ellimoottil CS, Qi J, et al. Intra-practice Urologist-level Variation in Targeted Fusion Biopsy Outcomes. Urology. 2023. PMID: 37121355. doi:10.1016/j.urology.2023.04.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。